id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2010-P-0359-0007,FDA,FDA-2010-P-0359,"Attachment B - ""Product Description/Information, Surgiflo® Original, Surgicel ® Nu-Knit and Surgeicel® Fibrillar™"" - [Goodwin Procter, LLP - Citizen Petition ]",Supporting & Related Material,Background Material,2022-05-24T04:00:00Z,2022,5,,,2022-05-24T13:30:01Z,,0,0,0900006480b138bf
FDA-2010-P-0359-0006,FDA,FDA-2010-P-0359,"Attachment A - ""Product Description/Information, Surgiflo"" - [Goodwin Procter, LLP - Citizen Petition ]",Supporting & Related Material,Background Material,2022-05-24T04:00:00Z,2022,5,,,2022-05-24T13:29:29Z,,0,0,0900006480b13874
FDA-2010-P-0359-0009,FDA,FDA-2010-P-0359,MDR Record Analysis_Jan 2010-Mar 2022_LMG re: Supplement to Citizen Petition,Supporting & Related Material,Background Material,2022-05-24T04:00:00Z,2022,5,,,2022-05-24T13:31:55Z,,0,0,09000064850ce930
FDA-2010-P-0359-0008,FDA,FDA-2010-P-0359,Hemostatic agents – Absorbable - Revised re: Supplement to Citizen Petition,Supporting & Related Material,Background Material,2022-05-24T04:00:00Z,2022,5,,,2022-05-24T13:31:49Z,,0,0,09000064850ccaa4
FDA-2010-P-0359-0005,FDA,FDA-2010-P-0359,Supplement to Citizen Petition,Other,Letter(s),2022-05-18T04:00:00Z,2022,5,2022-05-18T04:00:00Z,,2022-05-24T00:45:13Z,,0,0,090000648508b407
FDA-2010-P-0359-0004,FDA,FDA-2010-P-0359,Interim Response to Goodwin Procter LLP. from CDRH,Other,Letter(s),2019-08-28T04:00:00Z,2019,8,2019-08-28T04:00:00Z,,2019-08-28T18:53:08Z,,0,0,0900006483ed552e
FDA-2010-P-0359-0003,FDA,FDA-2010-P-0359,Goodwin Procter LLP - Letter,Other,LET-Letter,2010-12-14T05:00:00Z,2010,12,2010-12-14T05:00:00Z,,2010-12-14T18:57:46Z,,0,0,0900006480bb615d
FDA-2010-P-0359-0001,FDA,FDA-2010-P-0359,"Goodwin Procter, LLP - Citizen Petition",Other,CP-Citizen Petition,2010-07-08T04:00:00Z,2010,7,2010-07-08T04:00:00Z,2010-07-03T03:59:59Z,2024-11-07T22:20:44Z,,1,0,0900006480b13840
FDA-2010-P-0359-0002,FDA,FDA-2010-P-0359,Acknowledgement Letter to Goodwin Procter LLP,Other,ACK-Acknowledgement Letter,2010-07-08T04:00:00Z,2010,7,2010-07-08T04:00:00Z,,2013-08-11T01:35:47Z,,0,0,0900006480b13a22